Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1518P - Treating cancer with unknown primary (CUP) in Germany – an economic perspective

Date

16 Sep 2021

Session

ePoster Display

Presenters

Bernhard Mörtl

Citation

Annals of Oncology (2021) 32 (suppl_5): S1102-S1110. 10.1016/annonc/annonc711

Authors

B.A. Mörtl1, D. Beier2, K. Hasselmann1, C.B. Westphalen3, K. Berger1

Author affiliations

  • 1 Department Of Medicine Iii, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 2 Epidemiology, InGef - Institute for Applied Health Research Berlin GmbH, 10117 - Berlin/DE
  • 3 Comprehensive Cancer Center Munich & Department Of Medicine Iii, Ludwig Maximilian University of Munich, 81377 - Munich/DE
More

Abstract 1518P

Background

Cancer of unknown primary (CUP) is a cause of major morbidity and mortality. Still, only limited information on epidemiology, treatment and economic data with regards to CUP syndrome exists. The objective of this study is to project economic consequences associated with treating CUP in Germany and to identify factors that drive the economic outcomes.

Methods

This is a retrospective cohort study based on anonymized German claims data (InGef research database). Observation period: 2014 - 2019. Inclusion criteria: ≥18y, inpatient or outpatient diagnosis of CUP per year (prevalent patients; ICD-10-Code: C80).

Results

The number of documented CUP per 100.000 increased between 2014 – 2019 by 47% (2014: 226; 2019: 332); a rate of 8% per year. Age and sex did not change over 5 years, mean 71 years (73; 18 - 104) and 52% male (2019). The TOP-5 antineoplastic and immunomodulating agents (ATC code L) were similar between 2014 - 2019 (Platinum-containing compounds, Pyrimidine analogues, Monoclonal antibodies, Taxane, Colony stimulating factors). Percentage, number and length of hospitalization were comparable (2014-2019): 84% were inpatient; mean 3 admissions (2; 0 – 25) and mean 19 days ppt (4; 0 - 365) in 2019. Mean costs were €12.894 ppt in 2014 (5.319; 0 – 457.248) and €14.148 in 2019 (6.139; 0 – 600.558). The proportion of costs in 2019 exemplary: inpatient care 46%, medicines 33%, outpatient care 13% and therapeutic aids 7%. Total annual mean costs increased by 76% between 2014 - 2019. Approximately 13% of all patients died in 2014 and 10% in 2019.

Conclusions

From a payers’ perspective, with more documented CUP cases, annual costs increased over the study period. The wide cost range reflects the heterogeneity of CUP syndrome and its management. Claims data were associated with some common limitations with regards to line of therapy or the identification of a primary tumour after a certain time. Furthermore, claims data do not include patient-reported outcomes. To allow for comprehensive health economic and outcome analyses, such information would be essential. Accordingly, future efforts should aim at different data sources, e.g. registries, electronic patient records, in order to provide a holistic view of treatment patterns, outcomes and costs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Roche.

Disclosure

C.B. Westphalen: Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Other, Travel Support: Bayer; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Invited Speaker: Celgene; Financial Interests, Personal, Other, Travel Support: Celgene; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Personal, Advisory Board: Rafael; Financial Interests, Personal, Other, Travel Support: RedHill; Financial Interests, Personal, Advisory Board: RedHill; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Other, Travel Support: Roche; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Other, Travel Support: Servier; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Advisory Board: Shire/Baxalta; Financial Interests, Personal, Invited Speaker: Sirtex; Financial Interests, Personal, Other, Travel Support: Taiho; Financial Interests, Personal, Invited Speaker: Taiho; Non-Financial Interests, Personal and Institutional, Research Grant: Roche; Non-Financial Interests, , Officer: AIO - Arbeitsgemeinschaft Internistische Onkologie (Germany). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings